文献速递肝病消化道肿瘤与早癌

仑伐替尼联合抗PD1在肝癌中的免疫调节效应及患者富集依据

Immunomodulatory Effects of Lenvatinib Plus Anti-Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma.
PubMed 文献 · Hepatology · 2021-09-27

该研究在小鼠肝癌模型中比较仑伐替尼单药、抗PD1单药及联合治疗的免疫调节作用,发现联合治疗可诱导肿瘤退缩并抑制TGFβ通路相关免疫抑制信号。基于免疫相关基因组特征,约22%的肝癌患者可能从联合治疗中获益。

要点

  • 联合治疗组小鼠肿瘤退缩且应答时间短于单药组(P < 0.001)。
  • 仅联合治疗显著抑制TGFβ通路相关免疫抑制信号并诱导免疫活性微环境(P < 0.05)。
  • 基于免疫基因组特征,22%肝癌患者可能为联合治疗潜在应答者。

核心结论

  • 仑伐替尼联合抗PD1通过激活免疫通路、减少Treg浸润和抑制TGFβ信号发挥独特免疫调节作用。
  • 基因特征可识别约20%对单药不敏感但可能从联合治疗获益的肝癌患者。

研究设计与样本

  • 在C57BL/6J小鼠中建立三种同种异体肝癌模型(皮下和原位),随机接受安慰剂、仑伐替尼、抗PD1或联合治疗。
  • 对肿瘤和血液样本进行流式细胞术、转录组和免疫组化分析。
  • 利用联合治疗相关基因特征在228例肝癌患者队列中识别潜在应答者。

主要发现

  • 小鼠中联合治疗导致肿瘤退缩且应答时间短于单药治疗(P < 0.001)。
  • 抗PD1单药诱导树突状细胞和T细胞浸润,仑伐替尼降低调节性T细胞(Treg)比例。
  • 仅联合治疗显著抑制与TGFβ通路相关的免疫抑制信号并诱导免疫活性微环境(P < 0.05 vs. 其他治疗)。
  • 基于人肝癌免疫相关基因组谱,22%患者被识别为超越单药治疗的潜在应答者,其肿瘤特征为Treg浸润、低炎症信号和VEGFR通路激活。

关键数值与推荐

  • 联合治疗 vs. 单药治疗小鼠肿瘤应答时间:P < 0.001。
  • 联合治疗 vs. 其他治疗抑制免疫抑制信号:P < 0.05。
  • 人肝癌队列中潜在联合治疗应答者比例:22%。

临床怎么用

  • 仑伐替尼联合抗PD1可能通过免疫调节增强抗肿瘤活性,支持该联合方案的临床探索。
  • 基于Treg浸润、低炎症信号和VEGFR通路激活的基因特征可能用于富集联合治疗潜在获益人群。

局限性

  • 研究主要基于小鼠模型,人体验证仅通过基因特征在回顾性队列中识别潜在应答者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Lenvatinib is an effective drug in advanced HCC. Its combination with the anti-PD1 (programmed cell death protein 1) immune checkpoint inhibitor, pembrolizumab, has generated encouraging results in phase Ib and is currently being tested in phase III trials. Here, we aimed to explore the molecular and immunomodulatory effects of lenvatinib alone or in combination with anti-PD1. APPROACH AND RESULTS: We generated three syngeneic models of HCC in C57BL/6J mice (subcutaneous and orthotopic) and randomized animals to receive placebo, lenvatinib, anti-PD1, or combination treatment. Flow cytometry, transcriptomic, and immunohistochemistry analyses were performed in tumor and blood samples. A gene signature, capturing molecular features associated with the combination therapy, was used to identify a subset of candidates in a cohort of 228 HCC patients who might respond beyond what is expected for monotherapies. In mice, the combination treatment resulted in tumor regression and shorter time to response compared to monotherapies (P < 0.001). Single-agent anti-PD1 induced dendritic and T-cell infiltrates, and lenvatinib reduced the regulatory T cell (Treg) proportion. However, only the combination treatment significantly inhibited immune suppressive signaling, which was associated with the TGFß pathway and induced an immune-active microenvironment (P < 0.05 vs. other therapies). Based on immune-related genomic profiles in human HCC, 22% of patients were identified as potential responders beyond single-agent therapies, with tumors characterized by Treg cell infiltrates, low inflammatory signaling, and VEGFR pathway activation. CONCLUSIONS: Lenvatinib plus anti-PD1 exerted unique immunomodulatory effects through activation of immune pathways, reduction of Treg cell infiltrate, and inhibition of TGFß signaling. A gene signature enabled the identification of ~20% of human HCCs that, although nonresponding to single agents, could benefit from the proposed combination.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Torrens L, Montironi C, Puigvehí M, et al. Immunomodulatory Effects of Lenvatinib Plus Anti-Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma. Hepatology. 2021. PMID: 34157147. doi:10.1002/hep.32023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。